PL2964258T3 - Przeciwciała, które wiążą się z IL-23 - Google Patents

Przeciwciała, które wiążą się z IL-23

Info

Publication number: PL2964258T3
Authority: PL; Poland
Prior art keywords: antibodies; bind
Prior art date: 2013-03-08

Application number

PL14761062T

Other languages

English (en)

Inventor

Catherine Brautigam Beidler

Stuart Willis Bright

Daniel Scott GIRARD

Kristine Kay Kikly

Original Assignee

Eli Lilly And Company

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-03-08

Filing date

2014-03-04

Publication date

2021-02-08

2014-03-04 Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company

2021-02-08 Publication of PL2964258T3 publication Critical patent/PL2964258T3/pl

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Rheumatology (AREA)
Dermatology (AREA)
Epidemiology (AREA)
Microbiology (AREA)
Mycology (AREA)
Hematology (AREA)
Diabetes (AREA)
Orthopedic Medicine & Surgery (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Obesity (AREA)
Neurology (AREA)
Physical Education & Sports Medicine (AREA)
Pain & Pain Management (AREA)
Transplantation (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

PL14761062T 2013-03-08 2014-03-04 Przeciwciała, które wiążą się z IL-23 PL2964258T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201361774732P	2013-03-08	2013-03-08
EP14761062.0A EP2964258B1 (en)	2013-03-08	2014-03-04	Antibodies that bind il-23
PCT/US2014/020064 WO2014137962A1 (en)	2013-03-08	2014-03-04	Antibodies that bind il-23

Publications (1)

Publication Number	Publication Date
PL2964258T3 true PL2964258T3 (pl)	2021-02-08

Family

ID=51488096

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL14761062T PL2964258T3 (pl)	2013-03-08	2014-03-04	Przeciwciała, które wiążą się z IL-23

Country Status (41)

Country	Link
US (3)	US9023358B2 (pl)
EP (3)	EP4311558A3 (pl)
JP (1)	JP6096938B2 (pl)
KR (2)	KR101775115B1 (pl)
CN (1)	CN105307681B (pl)
AP (1)	AP2015008708A0 (pl)
AR (1)	AR094877A1 (pl)
AU (1)	AU2014226094C1 (pl)
BR (1)	BR112015019611B1 (pl)
CA (1)	CA2901462C (pl)
CL (1)	CL2015002388A1 (pl)
CY (2)	CY1123589T1 (pl)
DK (1)	DK2964258T3 (pl)
EA (1)	EA031524B1 (pl)
EC (1)	ECSP15038626A (pl)
ES (1)	ES2822662T3 (pl)
FI (1)	FIC20230030I1 (pl)
FR (1)	FR23C1036I2 (pl)
HR (1)	HRP20201633T1 (pl)
HU (2)	HUE051357T2 (pl)
IL (2)	IL240731B (pl)
JO (1)	JOP20140049B1 (pl)
LT (2)	LT2964258T (pl)
LU (1)	LUC00318I2 (pl)
MA (1)	MA38382A1 (pl)
MX (1)	MX370396B (pl)
MY (1)	MY171226A (pl)
NL (1)	NL301247I2 (pl)
NO (1)	NO2023037I1 (pl)
PE (1)	PE20151529A1 (pl)
PH (1)	PH12015501994B1 (pl)
PL (1)	PL2964258T3 (pl)
PT (1)	PT2964258T (pl)
RS (1)	RS60928B1 (pl)
SG (1)	SG11201507176VA (pl)
SI (1)	SI2964258T1 (pl)
TN (1)	TN2015000348A1 (pl)
TW (1)	TWI636063B (pl)
UA (1)	UA123198C2 (pl)
WO (1)	WO2014137962A1 (pl)
ZA (1)	ZA201505285B (pl)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AR102417A1 (es) *	2014-11-05	2017-03-01	Lilly Co Eli	Anticuerpos biespecíficos anti-tnf- / anti-il-23
US20180291093A1 (en) *	2015-10-30	2018-10-11	Eli Lilly And Company	Anti-cgrp/anti-il-23 bispecific antibodies and uses thereof
AR111845A1 (es)	2017-05-03	2019-08-28	Lilly Co Eli	Anticuerpos biespecíficos anti-cgrp / anti-il-23 y usos de los mismos
TWI744617B (zh)	2018-03-30	2021-11-01	美商美國禮來大藥廠	治療潰瘍性結腸炎之方法
TWI725532B (zh)	2018-09-11	2021-04-21	美商美國禮來大藥廠	治療牛皮癬之方法
TWI850365B (zh)	2019-04-22	2024-08-01	美商美國禮來大藥廠	治療克隆氏症(crohn's disease)的方法
EP4045641A1 (en)	2019-10-15	2022-08-24	Eli Lilly and Company	Recombinantly engineered, lipase/esterase-deficient mammalian cell lines
EP4077378A1 (en)	2019-12-20	2022-10-26	NovaRock Biotherapeutics, Ltd.	Anti-interleukin-23 p19 antibodies and methods of use thereof
CN111718414B (zh) *	2020-06-12	2021-03-02	江苏荃信生物医药有限公司	抗人白介素23单克隆抗体及其应用
WO2022041390A1 (zh) *	2020-08-28	2022-03-03	江苏荃信生物医药股份有限公司	包含高浓度抗人白介素23单克隆抗体的低粘度液体制剂及其制备方法
AR123477A1 (es) *	2020-09-10	2022-12-07	Lilly Co Eli	Formulaciones de anticuerpos terapéuticos
CA3219846A1 (en)	2021-05-28	2022-12-01	Venkatesh Krishnan	Anti-il-23p19 antibody regulation of genes involved in ulcerative colitis
CN113698480B (zh) *	2021-09-18	2022-07-01	东大生物技术(苏州)有限公司	一组il-23单克隆抗体及其医药用途
JP2024536166A (ja)	2021-09-30	2024-10-04	イーライリリーアンドカンパニー	潰瘍性大腸炎における腸切迫感に関与する遺伝子の抗ｉｌ－２３ｐ１９抗体による調節
WO2024077113A1 (en)	2022-10-06	2024-04-11	Eli Lilly And Company	Methods of treating fatigue in ulcerative colitis
WO2024178157A1 (en)	2023-02-22	2024-08-29	Eli Lilly And Company	Regulation of genes in ulcerative colitis and the uses thereof
CN121079321A (zh)	2023-03-10	2025-12-05	伊莱利利公司	治疗溃疡性结肠炎的方法
WO2025083549A1 (en)	2023-10-16	2025-04-24	Sun Pharma Advanced Research Company Limited	Methods and combinations of inhibitors of il-23 pathway and modulators of s1p signaling pathway for the treatment of autoimmune disorders
US20250228864A1 (en)	2023-11-29	2025-07-17	Gilead Sciences, Inc.	Therapies for the treatment of inflammatory bowel disease
WO2026058045A1 (en)	2024-09-12	2026-03-19	Takeda Pharmaceutical Company Limited	Alpha4beta7 inhibitor and il-23 inhibitor combination therapy
WO2026060205A1 (en)	2024-09-13	2026-03-19	Eli Lilly And Company	PAN-ELR+ CXC CHEMOKINE ANTIBODIES AND IL-23p19 ANTIBODIES FOR THE TREATMENT OF ULCERATIVE COLITIS

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6060284A (en)	1997-07-25	2000-05-09	Schering Corporation	DNA encoding interleukin-B30
US7090847B1 (en)	1999-09-09	2006-08-15	Schering Corporation	Mammalian cytokines; related reagents and methods
US7422743B2 (en)	2000-05-10	2008-09-09	Schering Corporation	Mammalian receptor protein DCRS5;methods of treatment
ATE440864T1 (de)	2003-03-10	2009-09-15	Schering Corp	Verwendung von il-23-antagonisten; verwandte reagenzien
US8003108B2 (en)	2005-05-03	2011-08-23	Amgen Inc.	Sclerostin epitopes
EP2452694B1 (en) *	2005-06-30	2018-11-14	Janssen Biotech, Inc.	Anti-IL-23 antibodies, compositions, methods and uses
DE602006015830D1 (de) *	2005-08-25	2010-09-09	Lilly Co Eli	Anti-il-23-antikörper
CN101248088A (zh) *	2005-08-25	2008-08-20	伊莱利利公司	抗il-23抗体
LT1931710T (lt) *	2005-08-31	2017-03-27	Merck Sharp & Dohme Corp.	Rekombinantiniai anti-il-23 antikūnai
RS55963B1 (sr) *	2005-12-29	2017-09-29	Janssen Biotech Inc	Humana anti-il-23 antitela, kompozicije, metode i upotrebe
SG178804A1 (en) *	2007-02-23	2012-03-29	Schering Corp	Engineered anti-il-23p19 antibodies
DK2426144T3 (en)	2007-02-23	2019-01-07	Merck Sharp & Dohme	Manipulated Anti-IL-23P19 Antibodies
KR101123487B1 (ko)	2007-03-20	2012-03-23	일라이 릴리 앤드 캄파니	항?스클레로스틴 항체
TW200902554A (en) *	2007-05-08	2009-01-16	Genentech Inc	Cysteine engineered anti-MUC16 antibodies and antibody drug conjugates
WO2009082624A2 (en) *	2007-12-10	2009-07-02	Zymogenetics, Inc.	Antagonists of il-17a, il-17f, and il-23 and methods of using the same
EP2435480A1 (en) *	2009-05-27	2012-04-04	Ablynx N.V.	Biparatopic protein constructs directed against il-23
SG190006A1 (en) *	2010-11-04	2013-06-28	Boehringer Ingelheim Int	Anti-il-23 antibodies
US8679767B2 (en) *	2011-05-12	2014-03-25	Genentech, Inc.	Multiple reaction monitoring LC-MS/MS method to detect therapeutic antibodies in animal samples using framework signature peptides

2014
- 2014-02-25 TW TW103106335A patent/TWI636063B/zh active
- 2014-02-25 AR ARP140100582A patent/AR094877A1/es active IP Right Grant
- 2014-02-25 JO JOP/2014/0049A patent/JOP20140049B1/ar active
- 2014-03-04 HR HRP20201633TT patent/HRP20201633T1/hr unknown
- 2014-03-04 AP AP2015008708A patent/AP2015008708A0/xx unknown
- 2014-03-04 ES ES14761062T patent/ES2822662T3/es active Active
- 2014-03-04 CA CA2901462A patent/CA2901462C/en active Active
- 2014-03-04 US US14/195,889 patent/US9023358B2/en active Active
- 2014-03-04 PH PH1/2015/501994A patent/PH12015501994B1/en unknown
- 2014-03-04 DK DK14761062.0T patent/DK2964258T3/da active
- 2014-03-04 CN CN201480012747.7A patent/CN105307681B/zh active Active
- 2014-03-04 PE PE2015001903A patent/PE20151529A1/es active IP Right Grant
- 2014-03-04 MY MYPI2015702927A patent/MY171226A/en unknown
- 2014-03-04 MA MA38382A patent/MA38382A1/fr unknown
- 2014-03-04 LT LTEP14761062.0T patent/LT2964258T/lt unknown
- 2014-03-04 UA UAA201508670A patent/UA123198C2/uk unknown
- 2014-03-04 RS RS20201236A patent/RS60928B1/sr unknown
- 2014-03-04 KR KR1020157024032A patent/KR101775115B1/ko active Active
- 2014-03-04 HU HUE14761062A patent/HUE051357T2/hu unknown
- 2014-03-04 EP EP23207282.7A patent/EP4311558A3/en active Pending
- 2014-03-04 SG SG11201507176VA patent/SG11201507176VA/en unknown
- 2014-03-04 JP JP2015561515A patent/JP6096938B2/ja active Active
- 2014-03-04 EP EP20193400.7A patent/EP3789037A1/en not_active Withdrawn
- 2014-03-04 AU AU2014226094A patent/AU2014226094C1/en active Active
- 2014-03-04 PL PL14761062T patent/PL2964258T3/pl unknown
- 2014-03-04 EA EA201591368A patent/EA031524B1/ru not_active IP Right Cessation
- 2014-03-04 WO PCT/US2014/020064 patent/WO2014137962A1/en not_active Ceased
- 2014-03-04 BR BR112015019611-0A patent/BR112015019611B1/pt active IP Right Grant
- 2014-03-04 PT PT147610620T patent/PT2964258T/pt unknown
- 2014-03-04 KR KR1020177024414A patent/KR20170103037A/ko not_active Ceased
- 2014-03-04 MX MX2015011959A patent/MX370396B/es active IP Right Grant
- 2014-03-04 SI SI201431653T patent/SI2964258T1/sl unknown
- 2014-03-04 EP EP14761062.0A patent/EP2964258B1/en active Active
2015
- 2015-05-01 US US14/702,124 patent/US9688753B2/en active Active
- 2015-07-22 ZA ZA2015/05285A patent/ZA201505285B/en unknown
- 2015-08-12 TN TN2015000348A patent/TN2015000348A1/en unknown
- 2015-08-20 IL IL240731A patent/IL240731B/en active IP Right Grant
- 2015-08-26 CL CL2015002388A patent/CL2015002388A1/es unknown
- 2015-09-08 EC ECIEPI201538626A patent/ECSP15038626A/es unknown
2017
- 2017-06-01 US US15/611,008 patent/US20170275356A1/en not_active Abandoned
2020
- 2020-01-14 IL IL272042A patent/IL272042B/en unknown
- 2020-11-16 CY CY20201101081T patent/CY1123589T1/el unknown
2023
- 2023-10-03 FI FIC20230030C patent/FIC20230030I1/fi unknown
- 2023-10-04 NO NO2023037C patent/NO2023037I1/no unknown
- 2023-10-06 CY CY2023021C patent/CY2023021I2/el unknown
- 2023-10-06 NL NL301247C patent/NL301247I2/nl unknown
- 2023-10-13 FR FR23C1036C patent/FR23C1036I2/fr active Active
- 2023-10-18 HU HUS2300036C patent/HUS2300036I1/hu unknown
- 2023-10-23 LU LU00318C patent/LUC00318I2/fr unknown
- 2023-10-23 LT LTPA2023530C patent/LTC2964258I2/lt unknown

Also Published As

Publication number	Publication date
PT2964258T (pt)	2020-11-06
LTC2964258I2 (pl)	2025-09-10
SI2964258T1 (sl)	2020-10-30
NO2023037I1 (no)	2023-10-04
AU2014226094A1 (en)	2015-08-27
LTPA2023530I1 (pl)	2023-11-10
LUC00318I2 (pl)	2026-02-02
AU2014226094C1 (en)	2024-10-24
DK2964258T3 (da)	2020-09-14
MX370396B (es)	2019-12-11
EA031524B1 (ru)	2019-01-31
EA201591368A1 (ru)	2015-12-30
FR23C1036I2 (fr)	2024-10-04
EP2964258A1 (en)	2016-01-13
KR20170103037A (ko)	2017-09-12
CA2901462C (en)	2017-07-25
PH12015501994B1 (en)	2023-03-01
HK1212252A1 (en)	2016-06-10
CY2023021I2 (el)	2024-09-20
SG11201507176VA (en)	2015-10-29
EP3789037A1 (en)	2021-03-10
MY171226A (en)	2019-10-03
EP2964258A4 (en)	2016-10-12
JP6096938B2 (ja)	2017-03-15
ES2822662T3 (es)	2021-05-04
CN105307681B (zh)	2018-06-26
CL2015002388A1 (es)	2016-03-04
NL301247I2 (nl)	2023-11-01
CY1123589T1 (el)	2022-03-24
HUE051357T2 (hu)	2021-03-01
CA2901462A1 (en)	2014-09-12
BR112015019611A2 (pt)	2017-08-22
US20150232552A1 (en)	2015-08-20
NZ711147A (en)	2021-03-26
TN2015000348A1 (en)	2017-01-03
RS60928B1 (sr)	2020-11-30
AP2015008708A0 (en)	2015-09-30
MA38382A1 (fr)	2017-11-30
IL240731A0 (en)	2015-10-29
FIC20230030I1 (fi)	2023-10-03
IL272042A (en)	2020-02-27
TWI636063B (zh)	2018-09-21
EP4311558A3 (en)	2024-04-10
EP2964258B1 (en)	2020-09-02
AU2014226094B2 (en)	2016-06-23
IL272042B (en)	2021-07-29
EP4311558A2 (en)	2024-01-31
HUS2300036I1 (hu)	2024-07-28
JP2016510744A (ja)	2016-04-11
US9688753B2 (en)	2017-06-27
FR23C1036I1 (fr)	2023-12-08
AR094877A1 (es)	2015-09-02
CN105307681A (zh)	2016-02-03
NL301247I1 (nl)	2023-10-11
US20170275356A1 (en)	2017-09-28
HRP20201633T1 (hr)	2020-12-25
BR112015019611B1 (pt)	2023-05-02
WO2014137962A1 (en)	2014-09-12
IL240731B (en)	2020-01-30
ZA201505285B (en)	2017-11-29
CY2023021I1 (el)	2024-02-16
KR20150113202A (ko)	2015-10-07
JOP20140049B1 (ar)	2021-08-17
ECSP15038626A (es)	2015-11-30
US9023358B2 (en)	2015-05-05
MX2015011959A (es)	2016-04-07
PH12015501994A1 (en)	2016-01-11
PE20151529A1 (es)	2015-10-28
TW201520225A (zh)	2015-06-01
KR101775115B1 (ko)	2017-09-05
US20140255422A1 (en)	2014-09-11
LT2964258T (lt)	2020-10-12
UA123198C2 (uk)	2021-03-03

Publication	Publication Date	Title
HUS2300036I1 (hu)	2024-07-28	IL-23 kötõ antitestek
ZA201808451B (en)	2021-04-28	Anti-fcrh5 antibodies
IL275103A (en)	2020-07-30	Antibody Formulations
GB201322583D0 (en)	2014-02-05	Antibodies
IL244712A0 (en)	2016-04-21	Anti-pdl1 antibody compositions
SG11201509361TA (en)	2015-12-30	Novel antibodies
ZA201506568B (en)	2017-11-29	Anti-tnf-anti-il-17 bispecific antibodies
ZA201601437B (en)	2018-08-29	Antibodies
GB201308658D0 (en)	2013-06-26	Antibodies
GB201315486D0 (en)	2013-10-16	Antibodies
GB201300706D0 (en)	2013-02-27	Antibody
IL245488A0 (en)	2016-06-30	Anti- ccl17 antibodies
GB201312226D0 (en)	2013-08-21	Improved antibodies
SG11201604503XA (en)	2016-07-28	Cytotoxic antibody
GB201318283D0 (en)	2013-11-27	Antibodies
GB201301845D0 (en)	2013-03-20	Antibody delivery